Get weight loss medication from a trusted Chicago-based medical group—not an online start-up. We provide flexible payment options, allowing you to use insurance or self-pay, with no hidden fees. Plus, you’ll have monthly check-ins with a real medical provider, ensuring personalized support and expert guidance every step of the way.
Reach an ideal body weight with GLP medication and guidance from our team of experts. Our Chicago medical providers prescribe Mounjaro®, Zepbound®, Ozempic® and Wegovy®. We always strive to get insurance coverage for our patients, and we accept all major PPO insurance plans. If your insurance denies weight loss, we will offer you self pay options:
Zepbound from Lilly Direct:
Wegovy from NovoCare:
An appointment with your provider is required for refills of either medication. You may use insurance for this visit, or self-pay $100.
*Based on self-reported data from Innovative Care patients on a personalized treatment plan including compounded GLP-1 injections, along with a reduced calorie diet and exercise. Customers reported their weight at their initial medical consultation and their first check-in approximately 8 weeks later. Stopping weight loss treatment has been shown to result in weight regain. Individual results may vary.
Our program includes an online consultation and follow up appointments from the comfort of your home, a personalized care plan provided by a licensed medical provider, medically supervised weight loss prescriptions, and ongoing care and support including monthly 1:1 telemedicine appointments. Want to stop in? We have four primary care locations and our experts are always available when needed.
Ready to lose weight? Let Innovative Primary Care lead the way. We believe medical weight loss should be guided by an expert and closely monitored. Innovative Care accepts insurance for weight loss, and we offer a self-pay option for individuals who can not use medical insurance for weight loss.
The first visit will be approximately 30 minutes. We’ll focus on health history, weight goals and expectations. We’ll explain how blood sugar regulation leads to weight loss and prescribe GLP medication (Ozempic®, Mounjaro®, Wegovy®, Zepbound®). We always try to use medical insurance for FDA approved weight loss medication before offering you self-pay options.
If your insurance covers weight loss, you will pick up your medication from the pharmacy and see an Innovative Primary Care provider 2x/month via telemedicine to ensure you’re on track. If your insurance denies coverage for weight loss, we will offer you self-pay options.
Do you have questions?
Email us at [email protected]
Schedule a follow up appointment.
All patients must reside in Illinois.
We work hard to get insurance coverage for FDA approved GLP medications. If your insurance denies coverage, we will offer you self-pay options.
We are a Chicago medical group with several locations, not one of those online only companies. Enjoy the convenience of online appointments, with the peace of mind of knowing we have a clinic just down the street.
We prescribe FDA approved injectable GLP medication and offer guidance from our team of weight loss experts. We offer real medications from real providers to help you achieve real results.
Read below for answers to the most commonly asked questions. Still unsure or need help?
Email us at [email protected]
GLP (glucagon-like peptide) receptor agonists are a class of medications that have been approved by the FDA for the treatment of type 2 diabetes and for weight loss. These medications work by mimicking the effects of the hormone GLP-1, which is naturally produced in the body to stimulate insulin secretion and suppress appetite. Some examples of GLP receptor agonists include exenatide (Byetta®, Bydureon®), liraglutide (Victoza®, Saxenda®), semaglutide (Ozempic®, Wegovy®) and tirzepatide (Zepbound®, Mounjaro®). These medications can be administered by injection and may be used in combination with other weight loss medications, such as metformin or a sulfonylurea. It’s important to note that these medications are only available by prescription and should be used under the guidance of a healthcare professional.
GLP-1 (glucagon-like peptide-1) receptors are a type of G protein-coupled receptor (GPCR) found on the surface of cells in the pancreas, brain, and gut. When GLP-1 binds to these receptors, it activates a cascade of intracellular signaling pathways that lead to a number of physiological effects.
In the pancreas, GLP-1 binding to its receptors stimulates the secretion of insulin, which helps to lower blood sugar levels. This effect is particularly important in people with type 2 diabetes, as it can improve glucose control and reduce the risk of complications associated with high blood sugar.
In the brain, GLP-1 binding to its receptors can suppress appetite and reduce food intake, which may contribute to weight loss. This effect is thought to be mediated by GLP-1’s ability to inhibit the activity of hypothalamic neurons that promote hunger and to stimulate the activity of neurons that promote satiety.
In the gut, GLP-1 binding to its receptors can slow down the emptying of the stomach, which can also help to reduce food intake and promote weight loss.
GLP-1 receptor agonists are medications that mimic the effects of GLP-1 by binding to and activating the GLP-1 receptors. These medications can be used to treat type 2 diabetes and as an adjunct therapy for weight loss.
Many insurance companies cover weight loss medication, but it is dependent on the plan and the individual. We always try to get insurance to cover weight loss medication for our patients. This includes doing a pre-authorization and appealing when necessary. Unfortunately, this is not always possible. If your insurance plan denies coverage for weight loss, we will offer you self pay options, which include Zepbound (starting at $349/month for the lowest dose) and Wegovy ($499/month).
The cost of weight loss medication depends on whether or not your insurance plan covers weight loss medication. We always try to use medical insurance first, but we offer patients self pay Zepbound ($349 to $499/month) or Wegovy ($499/month) when insurance does not cover weight loss.
Yes, we are only licensed in Illinois and therefore can only see Illinois residents.
*Disclaimer: The FDA-approved brand name drugs, such as Saxenda®, Victoza®, Wegovy®, and Ozempic® are exclusively available from the Novo Nordisk™ company. Mounjaro™ is exclusively available from Eli Lilly and Company™. Innovative Care does not claim any affiliation with, or endorsement from, the above mentioned products or entities. We do not offer any of the above mentioned products, anyone seeking said products should discuss options with their licensed healthcare provider or pharmacist. Wegovy® (semaglutide) and Ozempic® (semaglutide) are not compounded. Wegovy® (semaglutide) is FDA-approved for weight loss. Ozempic® (semaglutide) is FDA-approved for type 2 diabetes treatment but may be prescribed off-label for weight loss at a healthcare provider’s discretion. A healthcare provider may prescribe a compounded drug if determined that it is medically appropriate and necessary for you.
Weight loss medications are prescribed based on what your provider determines is medically appropriate and necessary for you. This may include prescribing generic drug products, and/or compounded products if appropriate and necessary. Compounded drug products are not approved nor evaluated for safety, efficacy, or quality by FDA. Medications are part of the Innovative Care Weight Loss program, which also includes a reduced calorie diet and increased physical activity.
GLP-1 receptor agonists—including semaglutide, liraglutide, dulaglutide, and tirzepatide—have been prescribed (on-and-off label) for weight management, including obesity, along with a reduced caloric diet and increased physical activity. Take precaution with, and read all warnings concerning, GLP-1s, as they may cause serious side effects, including a risk of thyroid c-cell tumors. Do not use if you or your family have a history of a type of thyroid cancer called MTC (medullary thyroid carcinoma) or MEN 2 (multiple endocrine neoplasia syndrome).